Table 2.
Median (IQR) of Labs by Progression
| |
Admission |
6 h |
||||||
|---|---|---|---|---|---|---|---|---|
| |
No progression |
Progression |
No progression |
Progression |
||||
| n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | |
| INR | 67 | 0.94 (0.89–1.03) | 62 | 0.99 (0.94–1.12) | 59 | 1 (0.93–1.07) | 54 | 1.08 (0.98–1.16) |
| PT (sec) |
67 | 12.8 (12.3–13.7) | 62 | 13.25 (12.78–14.55) | 59 | 13.4 (12.7–14.1) | 54 | 14.2 (13.18–15.03) |
| aPTT (sec) |
67 | 25.4 (23.1–28.3) | 62 | 25.8 (23.93–28.53) | 60 | 26.4 (23.40–28.25) | 54 | 27.1 (24.50–29.53) |
| FIB (mg/dL) |
67 | 307 (256–367) | 63 | 284 (236–377) | 60 | 281 (224–364) | 55 | 290 (230–352) |
| Plt ( × 103/μL) |
68 | 242 (193–270) | 69 | 217 (160–267) | 29 | 217 (171–243) | 33 | 181 (139–252) |
| F1 + 2 (pg/mL) |
40 | 273 (210–349) | 46 | 264 (156–373) | 39 | 271 (193–353) | 43 | 233 (158–394) |
| TAT (μg/mL) |
47 | 409 (186–524) | 47 | 320 (188–510) | 43 | 338 (180–514) | 42 | 340 (166–490) |
| D-DI (μg/mL) |
64 | 0.57 (−0.64 to 1.48) | 67 | 1.64 (0.77–2.68) | 61 | 0.88 (0.14–1.50) | 60 | 1.9 (1.07–2.91) |
| PAI-1 (pg/mL) |
67 | 9355 (7201–21,800) | 68 | 9346 (5934–25,904) | 61 | 7033 (5557–16,455) | 60 | 10,408 (7303–19,843) |
| tPA (pg/mL) |
67 | 1306 (578–2183) | 68 | 1464 (740–2685) | 61 | 794 (396–1319) | 61 | 922 (636–1401) |
| LY30 (%) |
69 | 0.6 (0–2) | 69 | 0.3 (0.00–1.35) | 58 | 0.35 (0.00–1.43) | 59 | 0.4 (0.0–1.8) |
INR, international normalized ratio; PT, prothrombin time; aPTT, activated partial thromboplastin time; FIB, fibrinogen; Plt, platelets; F1 + 2, prothrombin fragments 1 + 2; TAT, thrombin-antithrombin; D-DI, D-dimer; PAI-1, plasminogen activator inhibitor 1; tPA, tissue plasminogen activator; LY30, lysis at 30 min; IQR, interquartile range.